Bioelectronic medicine最新文献

{"title":"Participant-centered tolerability of transcutaneous auricular vagus nerve stimulation: insights from two crossover studies.","authors":"Gabriel Gonzalez, Maximillian O'Malley, Jessica Bolanos, Danielle Taylor, Lisa M McTeague, Adrian Canepa, Marlon L Wong","doi":"10.1186/s42234-026-00206-y","DOIUrl":"10.1186/s42234-026-00206-y","url":null,"abstract":"<p><p>BACKGROUND: Transcutaneous auricular vagus nerve stimulation (taVNS) is a promising noninvasive technique for modulating parasympathetic activity, yet optimal stimulation parameters and comprehensive tolerability profiles remain undefined. Traditional assessments of taVNS tolerability have focused narrowly on safety and adverse events, overlooking participant comfort and subjective experience, which are critical factors for adherence and clinical translation. METHODS: We conducted two randomized crossover trials in healthy adults to evaluate the tolerability of taVNS across different stimulation parameters. Study 1 compared two monophasic duty cycles (30 s on/30 s off vs. 10 s on/10 s off), while study 2 compared monophasic and biphasic waveforms. Tolerability was assessed using questionnaires and semi-structured interviews, with secondary outcomes including heart rate variability (HRV), pain sensitivity, and transcranial magnetic stimulation (TMS) measures of corticospinal excitability and intracortical inhibition/facilitation. RESULTS: Both studies demonstrated high tolerability across all taVNS conditions, with low median ratings for pain and irritation. The most common sensations were tingling, tickling, or pricking, reported by the majority of participants but rated as mild. Qualitative analysis revealed nuanced preferences related to comfort, perceived effectiveness, and ease of adjustment to stimulation. No significant differences in secondary physiological outcomes were observed between conditions, though trends suggested parameter-specific effects on HRV and pain sensitivity. CONCLUSIONS: Our findings highlight that taVNS is well tolerated in healthy adults, regardless of duty cycle application or waveform, when tolerability is defined to include comfort and participant experience. Incorporating these dimensions into tolerability assessments may enhance protocol optimization and support broader adoption of taVNS in clinical practice. Further research in clinical populations is warranted. TRIAL REGISTRATION: https://clinicaltrials.gov , identifiers (NCT06381102 and NCT06614933). </p>","PeriodicalId":72363,"journal":{"name":"Bioelectronic medicine","volume":"12 1","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13154589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vagus nerve stimulation in Crohn's disease: long-term outcomes, mechanistic insights, and the promise of non-invasive approaches.","authors":"Valérie Sinniger, Sonia Pellissier, Bruno Bonaz","doi":"10.1186/s42234-026-00205-z","DOIUrl":"10.1186/s42234-026-00205-z","url":null,"abstract":"<p><p>BACKGROUND: The vagus nerve (VN) has anti-inflammatory properties. We have previously reported in a 1-year pilot study that VN stimulation (VNS) improved patients with active Crohn’s disease (CD). In this paper, we present the results of the long-term follow-up of these CD patients (between four and ten years) and raise questions about the use of VNS in inflammatory bowel disease. METHODS: At the end of the pilot study, the 7 patients who ended the pilot study (corresponding to a 1-year active VNS), accepted to continue VNS as well as the 2 patients retrieved from the study, because of an early worsening (at 3 months of VNS) of their disease. Patients were then followed-up twice a year as far as possible with clinical and biological evaluation. Ileo-colonoscopy, as well as intestinal ultrasound evaluation were performed as far as possible. Vagal tone was evaluated by heart rate variability (HRV). The state perceived digestive pain score and the anxiety and depression score were also evaluated. RESULTS: Over a decade-long follow-up of nine CD patients implanted with VNS, sustained clinical benefits were observed despite heterogeneous disease courses and treatment histories. Three patients achieved long-term remission under VNS alone, without any additional therapy at 10 years. Several others initially controlled disease activity with VNS alone for 3–7 years before required biologics or surgery, most often during COVID-19. Clinical, biological, and endoscopic markers generally improved or stabilized, with relapse episodes responding to added standard therapies when needed. Autonomic data showed increased median parasympathetic HRV (HFnu) after implantation, persisting over six years despite interindividual variability. Median anxiety–depression scores decreased below clinical thresholds, and digestive pain shifted from moderate to low within the first year and remained low thereafter. Overall, long-term VNS was feasible, well tolerated, and associated with durable symptom control or remission in this small pilot cohort. CONCLUSIONS: This pilot study should primarily be viewed as a proof-of-concept demonstration that long-term invasive cervical VNS is feasible, safe, and acceptable for CD patients. It also highlights a potential therapeutic signal in a subset of individuals, supporting further investigation. </p>","PeriodicalId":72363,"journal":{"name":"Bioelectronic medicine","volume":"12 1","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13088470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147700812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel transcutaneous auricular neurostimulation electrode configuration for treatment of heavy menstrual bleeding: an open-label trial.","authors":"Christopher J Czura, Angela C Weyand, Maureen K Baldwin, Michael Recht, Caroline G Benner, Kimiko Harada, Brooke L Wade, Meghan Luellen, Michael J Darrow, Melanie A McWade, Alejandro Covalin, Navid Khodaparast","doi":"10.1186/s42234-026-00203-1","DOIUrl":"10.1186/s42234-026-00203-1","url":null,"abstract":"<p><p>BACKGROUND: Electrical stimulation of the cervical vagus nerve reduces traumatic blood loss in models of soft tissue injury. This pathway, termed the neural tourniquet, can be accessed with a transcutaneous auricular neurostimulation (tAN) targeting vagus and trigeminal nerve branches on and around the ear. The cymba concha is the most targeted dermatome to activate the auricular branch of the vagus nerve (ABVN); however due to variable ear anatomy, participants can report electrode discomfort leading to reduced treatment compliance and device usability. This study examined a novel electrode configuration to improve hemostasis during menstruation and device usability. METHODS: This open-label pilot trial (NCT06814028) sought to determine whether the use of tAN reduced menstrual blood loss in women with heavy menstrual bleeding (HMB). The device included a novel electrode configuration through which the auricular branch of the vagus nerve (ABVN) was targeted posterior to the auricle, near the mastoid process. Participants with a history of heavy menstrual bleeding gave informed consent to participate in an IRB-approved, decentralized clinical trial. Participants were followed for three consecutive menstrual cycles, during which estimated daily blood loss using a validated pictorial blood loss assessment chart (PBAC) and menstrual symptoms were recorded at the end of each menstruation. During the first menstruation, baseline PBAC and menstrual symptom scores were measured without the use of tAN. During the second menstruation, participants self-administered two 1-h sessions of tAN daily throughout menstruation; during the third menstruation, participants self-administered one 2-h session of tAN daily throughout menstruation. The PBAC was also used to calculate the duration of each menstruation, defined by the use of menstrual products. Student’s paired T-test was used to compare mean outcome scores to baseline. RESULTS: Use of the novel electrode design to deliver tAN was associated with lower PBAC scores and reduced duration of menstruation as compared with baseline. Notably, device usability surveys of participants revealed high device satisfaction scores, including comfort of the novel electrode configuration. CONCLUSIONS: These pilot results suggest that stimulating the ABVN posterior to the auricle is effective, safe and feasible for reducing menstrual blood loss in women with HMB. </p>","PeriodicalId":72363,"journal":{"name":"Bioelectronic medicine","volume":"12 1","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13049727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147617237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neural Interfaces for Bioelectronic Medicine.","authors":"Dimitrios A Koutsouras, Geert Langereis","doi":"10.1186/s42234-026-00204-0","DOIUrl":"10.1186/s42234-026-00204-0","url":null,"abstract":"<p><p>Bioelectronic medicine (BEM) is an emerging scientific field that aims to revolutionize the way we understand and treat disease by using electrical impulses for diagnosis and therapy. It is an interdisciplinary endeavour that draws on advances in microelectronics, information technology, materials science, and medicine, and it holds strong promise for addressing currently unmet medical needs. At its core, BEM seeks to develop implantable devices capable of modulating neuronal circuits and biological functions in a precise, targeted, and adaptable manner. Neural interfaces play a pivotal role within this therapeutic paradigm, as they must safely probe and interact with the nervous system while maintaining long‑term stability and biocompatibility. This editorial introduces the papers published in our collection “Neural Interfaces for Bioelectronic Medicine”. The included works present the clinical landscape of neuromodulation, examine mechanisms of device failure and reliability, introduce electrode technologies with improved biocompatibility and selectivity, and explore the therapeutic potential of alternative neuromodulation strategies, such as ultrasound and magnetoelectric nanoparticle‑based approaches, supported by computational models. Together, these contributions highlight both the opportunities and the challenges that must be addressed for bioelectronic medicine to fully flourish. They also identify the key technological advancements that will shape the future of neural interfaces and enable the next generation of bioelectronic therapies. We hope you enjoy this collection as much as we did.</p>","PeriodicalId":72363,"journal":{"name":"Bioelectronic medicine","volume":"12 1","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13032225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147534978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virtual reality volumetric rendering versus cross-sectional imaging for pancreatic cancer resectability assessment: a pilot randomized controlled reader study.","authors":"Karl Eisenträger, Kaya Saribeyoglu, Uli Fehrenbach, Matthäus Felsenstein, Lea Timmermann, Pedro Lua Machado Pereira, Wenzel Schöning, Benjamin Strücker, Johann Pratschke, Andreas Pascher, Thomas Malinka, Igor Maximilian Sauer, Haluk Morgul, Moritz Queisner","doi":"10.1186/s42234-026-00202-2","DOIUrl":"10.1186/s42234-026-00202-2","url":null,"abstract":"<p><p>BACKGROUND: Current imaging assessment for pancreatic cancer resectability demonstrates problematic inter-observer variability, with only fair-to-moderate agreement among experienced raters. Virtual reality technology offers stereoscopic three-dimensional visualization that may improve diagnostic accuracy and agreement. However, optimal visualization strategies for clinical adoption remain unclear. METHODS: Ten hepatopancreatobiliary surgeons from two high-volume centers were randomized 1:1 to assess twelve contrast-enhanced CT cases using either VR volumetric rendering or CSI. Primary outcomes included inter-rater agreement, diagnostic accuracy against expert reference standard, assessment time, and surgeon confidence. Statistical analysis employed Fleiss’ κ for inter-rater agreement and two-sided Mann–Whitney U tests on surgeon-level summary measures for between-group comparisons. RESULTS: CSI display on 2D screens achieved substantial inter-rater agreement for resectability assessment (κ = 0.609) while VR demonstrated only slight agreement (κ = 0.127). Diagnostic accuracy was superior with CSI (84.7% vs. 79.7%), with the most pronounced difference in resectability determination (83.3% vs. 58.3%, p = 0.033). VR users reported significantly lower confidence (4.85 ± 1.15 vs. 6.32 ± 0.77, p = 0.028). Assessment times were comparable between groups (median 313.5 s vs. 327.5 s, p = 1.00). CONCLUSIONS: In this preliminary investigation, our VR visualization strategy demonstrated lower diagnostic accuracy and inter-rater agreement than CSI. However, prior studies suggest that VR systems employing alternative, hybrid visualization approaches may improve inter-rater agreement, indicating that visualization strategy, rather than VR technology per se, is the primary determinant of utility. TRIAL REGISTRATION: DRKS00033932 (German Clinical Trials Register), registered prospectively. </p>","PeriodicalId":72363,"journal":{"name":"Bioelectronic medicine","volume":"12 1","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12969899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147379802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A robust, real‑time telemetry protocol for miniaturized neural implants using off‑the‑shelf hardware.","authors":"Mohamed Elgohary, Michael Recine, Jason Wong, Timir Datta-Chaudhuri","doi":"10.1186/s42234-026-00201-3","DOIUrl":"10.1186/s42234-026-00201-3","url":null,"abstract":"<p><p>BACKGROUND: Wireless telemetry from fully implanted, millimeter-scale neuromodulation devices is constrained by tight power budgets, inefficient antennas, and in-body attenuation. Standard protocols (e.g., BLE) offer mature ecosystems but exhibit throughput shortfalls and reduced robustness under non-ideal operating conditions. This study introduces the Neural Real-Time Telemetry Protocol (NRTP), a 2.4 GHz, half-duplex protocol designed to address the unmet need for reliable, real-time neural telemetry from miniaturized implants using off-the-shelf hardware, without custom electronics or ASICs. METHODS: NRTP was implemented on commercial 2.4 GHz hardware with static-length packets, immediate acknowledgments, bounded retransmissions, and single RF channel operation. We evaluated three mitigation strategies—retries, sample-level interleaving, and data overlapping—individually and in combination, and defined a quantitative evaluation metric that prioritizes data quality and power draw. Using identical hardware for NRTP and BLE, we performed controlled sweeps of received signal strength, tested multiple payload lengths and timing configurations, and measured throughput, data loss, and current draw. RESULTS: NRTP sustained zero data loss down to -75 dBm, whereas BLE performance degraded below -55 dBm due to throughput shortfalls under interference and deferred unlimited retries. Interleaving converted contiguous gaps into half-rate segments, delaying score decline at lower received signal strength; overlapping improved robustness but its doubled packet rate requirement was power-prohibitive for implant constraints. Across variants, NRTP delivered higher scores and lower variability over a wider operational range than BLE; BLE’s greater scores at high signal strength were driven by lower current consumption but fell off earlier with attenuation. The observed link-margin advantage for NRTP (up to ~ 23 dB at first loss; ~ 11 dB at 0.5% loss) implies ~ 3.2 × range in air, ~ 2.5 cm greater implant depth in tissue, or equivalently lower TX power for similar performance. CONCLUSIONS: NRTP provides robust telemetry for miniaturized implantable devices and is readily adoptable on commodity 2.4 GHz hardware. Its immediate, bounded retries and optional interleaving sustain throughput and minimize true data gaps under attenuation and interference, outperforming BLE across operating conditions relevant to small-animal implants. The resulting link-margin gains translate into practical benefits in coverage, implant depth, and power consumption, lowering barriers to chronic, closed-loop studies. </p>","PeriodicalId":72363,"journal":{"name":"Bioelectronic medicine","volume":"12 1","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12967005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scaling beyond the vagus nerve: historical and contemporary progress on electrode-based small-diameter peripheral nerve interfaces.","authors":"Max Li, Christine Ly, Jinghua Wen, Paritosh Rustogi, Ellis Meng","doi":"10.1186/s42234-025-00199-0","DOIUrl":"10.1186/s42234-025-00199-0","url":null,"abstract":"<p><p>Peripheral nerve interfaces play a central role in bioelectronic medicine. Since the early foundational experiments of Luigi Galvani in the 1770s, there have been over 250 years of development in electrical neuromodulation. Even so, current clinical approaches to interface with peripheral nerves are limited. Bioelectronic interfaces for small, branched nerves are of increasing interest to unlock new therapies and minimize off-target effects. This is facilitated by our growing understanding of peripheral nervous system physiology and advances in new materials and technologies. Therefore, this review examines historical and recent developments in FDA-approved peripheral nerve interfaces and investigational interfaces with an emphasis on approaches to target smaller nerves. Unmet needs in small nerve peripheral nerve interfaces are highlighted, followed by an examination of new strategies being pursued to address them. To conclude, ongoing challenges are summarized, revealing opportunities and prospects for future advancements.</p>","PeriodicalId":72363,"journal":{"name":"Bioelectronic medicine","volume":"12 1","pages":""},"PeriodicalIF":6.8,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12949514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147319156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring vagus nerve stimulation in postoperative delirium and dementia.","authors":"Rachel M Spicer, Peder S Olofsson, Fiona E Harrison","doi":"10.1186/s42234-026-00200-4","DOIUrl":"10.1186/s42234-026-00200-4","url":null,"abstract":"<p><p>Microglial activation and neuroinflammation, important aspects of neurodegeneration and accumulation of amyloid-pathology, is often exacerbated by peripheral inflammation following surgical procedures. Subsequent postoperative delirium is a predictor for long-term cognitive decline and increased rick of Alzheimer’s Disease, and perioperative strategies to reduce inflammatory responses, may be a potential avenue to mitigate postoperative complications. In this issue of Bioelectronic Medicine, Song et al. utilize percutaneous vagus nerve stimulation (pVNS) as a potential novel avenue for the attenuation of neuroinflammation and postoperative cognitive decline, which we have discussed in this commentary.</p>","PeriodicalId":72363,"journal":{"name":"Bioelectronic medicine","volume":"12 1","pages":"5"},"PeriodicalIF":6.8,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12922289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146229820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive neurobehavior and synaptic plasticity after vagus nerve stimulation in female rats: Interaction between estrous cycle and neurostimulation.","authors":"Laura K Olsen, Krysten A Jones, Birendra Sharma, Victoria T Ethridge, Nathan M Gargas, Sylvia D Cunningham, Joyce G Rohan, Candice N Hatcher-Solis","doi":"10.1186/s42234-025-00196-3","DOIUrl":"10.1186/s42234-025-00196-3","url":null,"abstract":"<p><p>A single session of vagus nerve stimulation (VNS) has been shown to improve cognition in male rodents, but the influence of sex on the effects of VNS on behavior and synaptic plasticity are poorly understood. The present study investigated cognitive performance and hippocampal (HC) electrophysiology/brain derived neurotrophic factor (BDNF) expression in female healthy adult rats to examine changes in cognition and synaptic plasticity after VNS paired training. A total of 44 female rats were utilized for the cognitive neurobehavior experiments and a total of 68 female rats were utilized for the electrophysiology experiments. Animals were divided into four groups: SHAM in diestrus (SHAM-D), SHAM in estrus (SHAM-E), VNS in diestrus (VNS-D), and VNS in estrus (VNS-E). Electrode wires were surgically implanted around the left cervical vagus nerve (VN) prior to stimulation and experimentation in female Sprague–Dawley rats. A single 30 min session of VNS (100 µs biphasic pulses, 30 Hz, 0.8 mA) was administered after neurobehavior training in a Novel Object Recognition (NOR) and a Passive Avoidance Task (PAT) and testing was performed 24 h after VNS. Electrophysiology recordings for input/output, long-term potentiation, spontaneous spiking, and paired-pulse facilitation (PPF) were collected 90 min after VNS to assess the functional effects of VNS on HC slices. Immunohistochemistry (IHC) was conducted on HC slices collected 48 h after VNS to quantify HC subregion specific changes in BDNF. Stimulated rats exhibited improved performance in the PAT when tested in the diestrus phase. Among all subjects, VNS increased response amplitude and decreased PPF. However, among those in diestrus VNS increased long-term potentiation (LTP) amplitude and frequency of spontaneous spiking, and decreased PPF in the CA1. Among those in estrus, VNS did not change LTP amplitude or PPF, but frequency of spontaneous spiking was increased. VNS and estrous cycle stage additionally influenced the HC expression of BDNF in the CA1 and CA2. These findings suggest that a single session of VNS can increase synaptic plasticity, but that an interaction between estrous cycle phase and VNS influences the effects of VNS in females. This study is among the first to investigate the influence of estrous cycle phase on cognitive neurobehavior and synaptic plasticity outcomes after VNS and contributes to the understanding of VNS-induced cognitive enhancement.</p>","PeriodicalId":72363,"journal":{"name":"Bioelectronic medicine","volume":"12 1","pages":"4"},"PeriodicalIF":6.8,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12862914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The sixth bioelectronic medicine summit: Neurotechnologies for individuals and communities.","authors":"Siyar Bahadir, Jacob T Robinson, Leslie R Morse, Paul B Yoo, Ralph Kern, Nathan S Makowski, Takashi D Y Kozai, Marat Fudim, Mary F Barbe, Hubert H Lim, Eric H Chang, Stavros Zanos","doi":"10.1186/s42234-025-00195-4","DOIUrl":"10.1186/s42234-025-00195-4","url":null,"abstract":"<p><p>The Sixth Bioelectronic Medicine Summit took place on March 4 and 5, 2025 at the Garden City Hotel in New York, and was co-hosted by the Feinstein Institutes for Medical Research (FIMR), Northwell Health and the University of Minnesota. The Summit brought together speakers and attendees from academia, medicine and industry to discuss the evolving landscape of neuromodulation and bioelectronic therapeutics. This year’s Summit was titled “Neurotechnologies for Individuals and Communities” and emphasized approaches that consider differences between subjects to deliver precision neuromodulation therapies, as well as approaches that expand the therapeutic footprint of neuromodulation to underserved populations and communities. The Summit included sessions covering basic and translational research, device development and commercialization, and emerging clinical applications. This meeting report summarizes the major events from the two days of the Summit, including keynote addresses, scientific sessions, discussion panels, award presentations, and sponsored talks.</p>","PeriodicalId":72363,"journal":{"name":"Bioelectronic medicine","volume":"12 1","pages":"3"},"PeriodicalIF":6.8,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12849451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146069054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}